Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
  • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
  • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
  • C07C311/46—Y being a hydrogen or a carbon atom
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the invention relates to compounds of the formula I.
• -OR 5 -N (R 5 ) 2l -NO 2 , -CN, -Hai, -NR 5 COA, -NR 5 COAr ' , -NR 5 SO 2 A, -NR 5 SO 2 Ar', -COOR 5 , -CON (R 5 ) 2 , -CONR 5 Ar ', -COR 6 , -COAr' or S (O) n A may be substituted;
• R 2 -N (R 5 ) 2 , -NR 5 COA, -NR 5 COAr, -NR 5 COOR 5 ;
• R 3 , R 4 independently of one another, -H, -A, -OR 5 , -N (R 5 ) 2 , -NO 2 , -CN, -Hai, -NR 5 COA, -NR 5 COAr ', -NR 5 SO 2 A, -NR 5 SO 2 Ar ', -COOR 5 ,
• R 6 , R 7 independently of one another -H, -A or - (CH 2 ) r Ar ';
• W - (CR 6 R 7 ) n -, - (OCR 6 R 7 ) 0 -, 1, 3-phenylene, 1, 3-phenylene-C (R 6 ) 2 -, 1, 4-phenylene, 1, 4-phenylene-C (R 6 ) 2 -;
• Ar unsubstituted or single, double or triple by -A, -Ar ', -Het,
• Ar ' unsubstituted or single, double or triple by -A, -OR 8 , -N (R 8 ) 2 , -N0 2 , -CN, -Hai, -NR 8 COA, -NR 6 S0 2 A, -COOR 8 , -CON (R 8 ) 2, -COR 8 , -S0 2 NR 8 or -S (0) n A substituted phenyl 0- or naphthyl;
• Het a mono-, dinuclear, saturated, unsaturated or aromatic heterocycle with 1 to 4 N, O and / or S atoms, bonded via N or C, which is unsubstituted or mono-, di- or triple by -A, - OR 6 , -N (R 6 ) 2 , -N0 2 , -CN, -Hai, -NR 6 COA, -NR 6 S0 2 A,
• the invention also relates to the optically active forms, the racemates, the diastereomers and the hydrates and solvates, e.g. Alcohololates, these compounds.
• the object of the invention was to find new compounds with valuable properties, in particular those which can be used for the production of medicaments.
• the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability.
• they show factor Xa inhibitory properties and can therefore be used to combat and prevent thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudication intermittently.
• the compounds of the formula I according to the invention can furthermore be inhibitors of the coagulation factors factor VIIa, factor IXa and thrombin of the blood coagulation cascade.
• the antithrombotic and anticoagulant effect of the compounds according to the invention is attributed to the inhibitory action against the activated coagulation protease, known under the name of factor Xa, or to the inhibition of other activated serine proteases such as factor VIIa, factor IXa or thrombin.
• Factor Xa is one of the proteases involved in the complex process of blood clotting. Factor Xa catalyzes the conversion of Prothrombin in thrombin. Thrombin cleaves fibrinogen into fibrin monomers which, after cross-linking, make an elementary contribution to thrombus formation. Activation of thrombin can lead to the occurrence of thromboembolic disorders. However, inhibition of thrombin can inhibit fibrin formation involved in thrombus formation.
• the measurement of the inhibition of thrombin can e.g. using the method of G.F. Cousins et al. in Circulation 1996, 94, 1705-1712.
• Inhibition of factor Xa can thus prevent thrombin from being formed.
• the compounds of formula I according to the invention and their salts interfere with the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.
• the inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
• a suitable method is e.g. by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223.
• the measurement of the inhibition of factor Xa can e.g. using the method of T. Hara et al. in thromb. Haemostas. 1994, 71, 314-319.
• the coagulation factor VIa initiates the extrinsic part of the coagulation cascade after binding to the tissue factor and contributes to the activation of the factor X to factor Xa. Inhibition of factor VIIa thus prevents the formation of factor Xa and thus the subsequent formation of thrombin.
• the inhibition of the factor VIIa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
• a common method for measuring the inhibition of factor VIIa is described, for example, by HF Ronning et al. in Thrombosis Research 1996, 84, 73-81.
• Coagulation factor IXa is generated in the intrinsic coagulation cascade and is also involved in the activation of factor X to factor Xa. Inhibition of factor IXa can therefore otherwise prevent factor Xa from being formed.
• the inhibition of factor IXa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
• a suitable method is e.g. by J. Chang et al. in Journal of Biological Chemistry 1998, 273, 12089-12094.
• the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine, in particular for combating and preventing thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication ,
• the invention further relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients.
• the invention further relates to pharmaceutical preparations containing at least one compound of the formula I and / or one of its physiologically acceptable salts.
• Suitable carriers are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin , Carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly.
• Tablets, pills, dragees, capsules, powders, granules, syrups, juices or drops are used in particular for oral use, suppositories for rectal use, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for parenteral use. for topical application of ointments, creams or powder.
• the new compounds can also be lyophilized and the lyophilizates obtained used, for example, for the production of injectables.
• the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active substances, eg one or more vitamins.
• auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, coloring, flavoring and / or several other active substances, eg one or more vitamins.
• the compounds of formula I and their physiologically acceptable salts can be used in the control and prevention of thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.
• thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication.
• the substances according to the invention are generally preferably administered in doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
• the daily dosage is preferably between about 0.02 and 10 mg / kg body weight.
• the specific dose for each patient depends on a wide variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination and combination of drugs and severity of the respective disease to which the therapy applies. Oral application is preferred.
• the compounds of the formula I and also the starting materials for their preparation are prepared by methods known per se, as described in the literature (for example in the standard works such as Houben-Weyl, methods of organic chemistry, Georg-Thieme-Verlag, Stuttgart) are and under reaction conditions that are known and suitable for the reactions mentioned. Use can also be made of variants which are known per se and are not mentioned here in any more detail.
• the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but immediately further reacted to the compounds of formula I.
• a synthesis with which compounds of the formula I can be prepared is generally presented below.
• the synthesis can be varied by choosing suitable starting compounds.
• the synthesis is intended to show, by way of example only, one possible way of representing compounds of the formula I.
• other synthetic routes can also be used for the display.
• the protected acid component A is reacted with the amine B to form a central amide bond to the compound C. Subsequently the carbamimidoyl group is reductively released to give the compound D and then the tert-butyl protective group is cleaved off in acid with trifluoroacetic acid, the active ingredient E being obtained as trifluoroacetate.
• the acid component A and the amine B can also be prepared by conventional synthetic methods.
• An exemplary synthesis is presented in Scheme 2 below.
• the phenol derivative F protected on the carbamine midoyl group is reacted with the protected ⁇ -bromocarboxylic acid G to give the compound H.
• the ester H is then saponified to give the carboxylic acid A.
• Bromine-nitro-benzene I is reacted with the boronic acid derivative J to form biphenyldehyde K.
• the nitro group is reduced to the amine to obtain the amine component B ⁇
• the bromine compound L is reacted with phthalimide potassium to give the compound M.
• the amine B is then released from this with hydrazine.
• Methylmorpholine was added and the mixture was stirred at room temperature for 18 hours.
• Example 4 3- (3-carbamimidoylphenyl) propionic acid (2-tert-butylsulfamoyl-biphenyl-4-yl) -amide acetate.
• Example A Injection glasses
• a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection jar contains 5 mg of active ingredient.
• a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
• a solution of 1 g of an active ingredient is prepared of the formula I, 9.38 g of NaH 2 PO 4 • 2H 2 O, 28.48 g Na 2 HPO 4 • 12 H 2 O and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
• Example D ointment
• 500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
• a mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
• Example F coated tablets
• Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
• Example G capsules
• each capsule contains 20 mg of the active ingredient.
• a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed sterile. Each ampoule contains 10 mg of active ingredient.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7632028

Family Applications (1)

Country Status (19)

Families Citing this family (11)

Family Cites Families (4)

• 2000
  • 2000-02-23 DE DE10008329A patent/DE10008329A1/de not_active Withdrawn
• 2001
  • 2001-02-22 JP JP2001561727A patent/JP2003524651A/ja active Pending
  • 2001-02-22 PL PL01356565A patent/PL356565A1/xx unknown
  • 2001-02-22 SK SK1199-2002A patent/SK11992002A3/sk unknown
  • 2001-02-22 BR BR0108607-3A patent/BR0108607A/pt not_active Application Discontinuation
  • 2001-02-22 RU RU2002123337/04A patent/RU2002123337A/ru unknown
  • 2001-02-22 WO PCT/EP2001/002034 patent/WO2001062717A1/de not_active Application Discontinuation
  • 2001-02-22 CZ CZ20022783A patent/CZ20022783A3/cs unknown
  • 2001-02-22 EP EP01927690A patent/EP1257530A1/de not_active Withdrawn
  • 2001-02-22 CN CN01805418A patent/CN1404467A/zh active Pending
  • 2001-02-22 CA CA002399018A patent/CA2399018A1/en not_active Abandoned
  • 2001-02-22 KR KR1020027010594A patent/KR20020091092A/ko not_active Application Discontinuation
  • 2001-02-22 US US10/204,455 patent/US20030135055A1/en not_active Abandoned
  • 2001-02-22 MX MXPA02008207A patent/MXPA02008207A/es unknown
  • 2001-02-22 AU AU2001254661A patent/AU2001254661A1/en not_active Abandoned
  • 2001-02-22 HU HU0300008A patent/HUP0300008A2/hu unknown
• 2002
  • 2002-07-09 ZA ZA200205482A patent/ZA200205482B/xx unknown
  • 2002-08-22 NO NO20023998A patent/NO20023998D0/no not_active Application Discontinuation
• 2003
  • 2003-07-09 HK HK03104902.6A patent/HK1052499A1/zh unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events